Peptide Health Lab

Longevity & cellular

MOTS-c

FOR RESEARCH PURPOSES ONLY

Also known as: Mitochondrial open reading frame of the 12S rRNA-c, Mitochondrial-derived peptide MOTS-c

Regulatory status
Research only
Evidence grade
Animal studies only

Last reviewed August 2, 2026 · 16 sources

What MOTS-c is and how it works

MOTS-c is a sixteen-amino-acid peptide, and the interesting part is where its instructions live. They sit inside the mitochondrial genome rather than the cell nucleus, in a short open reading frame within the 12S ribosomal RNA gene, which is what the name abbreviates.[1] That places it in a small family of mitochondrial-derived peptides alongside humanin, and it is the basis for the claim that mitochondria are signalling organs as well as power plants.[5]

The mechanism proposed in the discovery paper is unusually specific for a peptide of this kind. MOTS-c was reported to inhibit the folate cycle and the de novo purine biosynthesis tethered to it; the resulting accumulation of an intermediate activates AMP-activated protein kinase, the cell's low-energy sensor.[1] Skeletal muscle appeared to be the primary target organ.

A second mechanistic layer arrived later. Under metabolic stress, MOTS-c does not stay in the mitochondrion. It translocates into the nucleus and regulates nuclear gene expression, including stress-response genes.[7] A peptide encoded by one genome that travels to regulate the other is a genuinely novel piece of biology, and it is the reason the compound attracts attention well beyond its evidence base.[15]

Endogenous MOTS-c is measurable in human blood at concentrations in the nanogram-per-millilitre range,[6] and its expression in skeletal muscle and circulation has been reported to rise with exercise. That is where the "exercise mimetic" framing originates.[10]

What the research actually shows

Metabolism in mice. This is the deepest and most consistent layer. In the discovery work, treating mice with MOTS-c prevented both age-dependent and high-fat-diet-induced insulin resistance and prevented diet-induced obesity.[1] An untargeted metabolomic follow-up in diet-induced obese mice found that sphingolipid, monoacylglycerol, and dicarboxylate metabolism, three pathways upregulated in obesity and type 2 diabetes models, were reduced in MOTS-c-injected animals.[8]

Physical capacity and aging in mice. MOTS-c improved physical performance in young, middle-aged, and old mice, regulated nuclear genes related to metabolism and proteostasis, and altered myoblast adaptation to metabolic stress. An intermittent three-times-weekly schedule begun at 23.5 months of age, deep into a mouse lifespan, increased physical capacity and healthspan measures.[10] A separate study reported reduced myostatin and muscle-atrophy signaling.[11]

Other rodent protection models. MOTS-c suppressed ovariectomy-induced bone loss in mice through AMPK activation,[4] and reduced injury in a mouse model of lipopolysaccharide-induced acute lung injury.[9] These follow the familiar shape of a preclinical protection literature: a reproducible effect in a controlled injury paradigm, replicated across models rather than across species.

Humans, endogenous only. The human literature measures the peptide people already make. In a randomized acute-exercise study of thirty adults, endurance exercise significantly raised circulating humanin while MOTS-c showed only a non-significant trend, and resistance exercise raised neither.[12] Cross-sectional work has related plasma MOTS-c to metabolic variables with mixed results: concentrations were similar in lean and obese adults but correlated with insulin resistance only in the lean group,[6] positively associated with android and liver fat in people without diabetes,[13] and measured lower in obese children than in controls.[16]

Genetics. A short paper proposed that a polymorphism in the MOTS-c-encoding region of mitochondrial DNA, found specifically in a Northeast Asian population, might contribute to Japanese longevity. The authors offered it explicitly as a suggestion needing further research.[2]

Where the evidence is weak

This section is short to write and hard to argue with.

Nobody has been given this peptide in a published trial. Every human data point on this page comes from measuring endogenous MOTS-c in blood or muscle, the peptide a person's own mitochondria already make. There is no published study in which MOTS-c was administered to a human being, and therefore no human pharmacokinetics, no dose-finding, no adverse-event table, and no efficacy result of any kind.[15][14]

The human observational data does not agree with itself. If MOTS-c were a straightforward marker of metabolic health, its concentration would move in one direction as metabolic health worsened. It does not. Across three cohorts the associations run in different directions in different populations, which means there is no established physiological target and no coherent rationale for raising it.[6][13][16]

The human exercise result is weaker than the framing suggests. The "exercise-induced peptide" description rests substantially on one group's work. When an independent randomized study measured it directly, MOTS-c did not reach significance.[12]

Commercial interest is disclosed in the primary literature. Several of the foundational papers carry declarations that authors are consultants and shareholders in a company developing mitochondrial-peptide therapeutics.[10][8] The disclosure is published and appropriate; it is also a reason the field's most optimistic framing should be read alongside its data rather than instead of it.

The mouse results are exactly as strong and exactly as limited as mouse results usually are. A peptide that prevents diet-induced obesity in a mouse has cleared a bar that dozens of compounds have cleared without ever helping a person.

Long-term safety is unknown. The rodent studies were designed to detect metabolic and performance effects over weeks. Nothing in the published record speaks to sustained exposure in humans, and the proposed mechanism touches the folate and purine pathways, which are not casual targets.[1]

Legal and regulatory status

MOTS-c is not approved by the FDA for any indication, and it is not approved by other major regulators. It is not a dietary supplement ingredient and it is not an approved drug; material labeled MOTS-c is distributed for laboratory research use, which is why every mention of it on this site carries research-only framing.[14]

Its status in tested sport is no longer a matter of anticipation. The World Anti-Doping Agency names MOTS-c on the prohibited list itself, spelled out as the mitochondrial open reading frame of the 12S rRNA-c, as an example of an activator of AMP-activated protein kinase under section S4.4.1. Every substance in section S4 is prohibited at all times, in competition and out of it. The analytical-chemistry literature had flagged mitochondrial-derived peptides as likely sports-drug-testing targets years earlier, on the strength of their effects on skeletal muscle function and mitochondrial biogenesis.[3] Prohibited lists are still revised annually; an athlete subject to testing should confirm the current position with their governing body rather than rely on a reference page.

PHL does not sell peptides, does not tell anyone how to obtain them, and takes no position on how unapproved material reaches anyone. What the regulatory status means for a reader is narrower and more useful: there is no label, no approved manufacturer, no assigned indication, and no regulated quality standard behind anything labeled MOTS-c.[15]

Questions to bring to a provider

The productive version of this conversation is not "should I try MOTS-c." It is "here is the metabolic or performance problem I actually have. What has evidence behind it, and where does a peptide nobody has yet given to a human sit relative to that?" Questions worth raising:

  • What does the actual metabolic picture look like on fasting insulin, HbA1c, lipids, and body composition, and what does the standard-of-care evidence base offer for it?
  • Given that the entire efficacy literature is mouse work and the entire human literature is observational, what would have to be true for this to be worth considering at all?[14]
  • If glucose-lowering medication is already in use, what would an additional agent acting on the same axis do to hypoglycaemia risk?[1]
  • Does the proposed folate-cycle mechanism interact with anything currently prescribed, or with pregnancy planning?[5]
  • If competing in a tested sport, what does this year's prohibited list say?[3]
  • Which labs, body composition measures, or functional tests would make it possible to tell whether anything actually changed, rather than relying on how it feels?

A clinician who answers "there is no human trial to reason from" is describing the literature accurately.

Evidence by claim

Grades describe how strong the evidence is; the line under each grade describes what kind of studies it is. How we grade evidence.

Insulin sensitivity and diet-induced obesity
Animal studies only animal

In the discovery work, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity in mice, with skeletal muscle identified as the apparent target organ. A later metabolomic study in diet-induced obese mice reported reductions in sphingolipid, monoacylglycerol, and dicarboxylate metabolism pathways that are upregulated in obesity and type 2 diabetes models.

[1] [8]

Physical performance and age-related physical decline
Animal studies only animal

MOTS-c improved physical performance in young, middle-aged, and old mice, and treatment started at 23.5 months of age on an intermittent schedule increased physical capacity and healthspan measures. A separate study reported reduced myostatin and muscle-atrophy signaling. These are mouse results; no equivalent has been attempted in people.

[10] [11]

Bone loss after ovariectomy
Animal studies only animal

In ovariectomized mice, MOTS-c suppressed bone loss through AMPK activation. A single rodent model of surgical estrogen deprivation is a long way from postmenopausal osteoporosis in a person, and nothing has followed it into human study.

[4]

Acute inflammatory lung injury
Animal studies only animal

MOTS-c reduced lung injury in a mouse model of lipopolysaccharide-induced acute lung injury. This sits in the same category as the other rodent protection models, a reproducible effect in a controlled injury paradigm with no human follow-through.

[9]

Nuclear gene regulation as the proposed mechanism
Animal studies only in vitro · review

Under metabolic stress, MOTS-c translocates from the mitochondrion to the nucleus and regulates nuclear gene expression, including stress-response genes. That is a genuinely novel piece of biology and the strongest mechanistic result in the field. It is also cell-level work, and mechanism is not outcome.

[7] [5]

Endogenous MOTS-c response to exercise in humans
Anecdotal reports only human RCT · animal

This is the only human interventional evidence, and it is about the body's own peptide rather than an administered one. A randomized acute-exercise study assigned thirty adults to ten cycling, ten lifting, and ten controls. Circulating humanin rose significantly after endurance exercise while MOTS-c showed only a trend, and resistance exercise raised neither. The grade here is deliberately not the design grade: the study was randomized, but its result for MOTS-c was null, so grading this claim as randomized trial evidence would credit MOTS-c with a finding the trial did not produce. A separate study reported that exercise induces endogenous MOTS-c expression in human skeletal muscle and circulation, but that is the same group whose framing the randomized study failed to confirm.

[12] [10]

Circulating MOTS-c as a marker of metabolic health in humans
Anecdotal reports only human observational

Cross-sectional cohorts have measured plasma MOTS-c against metabolic variables with inconsistent results: concentrations similar between lean and obese adults but correlated with insulin resistance only in lean participants, positively associated with android and liver fat in people without diabetes, and decreased in obese children relative to controls. Observational, small, and pointing in different directions.

[6] [13] [16]

Human longevity
Anecdotal reports only review

A short hypothesis paper proposed that the m.1382A>C polymorphism in the MOTS-c-encoding region of mitochondrial DNA, which is specific to a Northeast Asian population, may be among the mechanisms behind Japanese longevity. The authors explicitly frame it as a suggestion requiring further research. No cohort was assembled and no association was measured in that paper. It is a three-page hypothesis piece rather than an observational study, and it is not evidence that the peptide extends life.

[2]

Any clinical effect of administered MOTS-c in humans
Anecdotal reports only review

No published trial has given MOTS-c to a person for any indication. Reviews describe therapeutic potential and call for exploitation of that potential, which is the language of a field that has not yet reached the clinic. The honest statement is that human efficacy data for this compound does not exist.

[15] [14]

FOR RESEARCH PURPOSES ONLY

Typical protocol range in the research

  • The route and schedule used across the published mouse efficacy work, expressed per kilogram of mouse body weight and given by intraperitoneal injection

    Intraperitoneal injection; the late-life healthspan experiment began treatment at 23.5 months of age on an intermittent three-times-weekly schedule [10] [1]

  • Endogenous plasma concentrations measured in lean and obese adults, a measurement of what the body already carries rather than an administered amount

    0.48 ± 0.16 ng/mL in lean participants and 0.52 ± 0.15 ng/mL in obese participants, a difference that was not statistically significant [6]

  • Humans, administered MOTS-c, any indication

    No published trial has administered MOTS-c to people; reviews of the field describe it as a candidate for therapeutic exploitation rather than an established therapy, and no human dose is established [15] [14]

The only entries with a real evidence base behind them are a rodent route and schedule and a human blood-level measurement. Neither is a human protocol. Circulating concentrations in the nanogram-per-millilitre range also say nothing about what an injected amount would need to be, because nobody has measured what happens to injected MOTS-c in a person.

Ranges are what published research reports, not a recommendation. PHL does not prescribe, and nothing here is personalized to you.

Side effects & safety signals

  • No established human safety profile

    Not established · Unknown. That is an absence of data, not a finding of safety. The peptide has never been administered to people in a published trial, so there is no adverse-event record, no dose-limiting toxicity, and no pharmacokinetic description to reason from.

    [15] [14]

  • Metabolic and glucose-lowering activity

    Consistently reported in rodent models · In mice, MOTS-c improved insulin sensitivity, prevented diet-induced insulin resistance and obesity, and altered plasma metabolite pathways associated with obesity and type 2 diabetes. That is the intended effect in those models, but in a person already taking insulin or another glucose-lowering medication, an additional agent acting on the same axis is a provider-discussion flag rather than a bonus.

    [1] [8]

  • Interference with the folate cycle and de novo purine biosynthesis

    Described as the primary proposed cellular mechanism · The mechanism the discovery paper proposes is inhibition of the folate cycle and the purine biosynthesis tethered to it, which is what leads to AMPK activation. That pathway is shared with several conventional drugs and with folate status generally. No study has examined what chronic interference means in a person, including in pregnancy, in someone on a folate antagonist, or in someone with a haematological condition.

    [1] [5]

  • No defined physiological target to restore

    Reported inconsistently across human cohorts · Human observational studies disagree about which direction circulating MOTS-c moves with metabolic disease: plasma concentrations were similar in lean and obese adults but correlated with insulin resistance only in the lean group, associated positively with android and liver fat in people without diabetes, and measured lower in obese children than in controls. Without a consistent direction, "restoring MOTS-c" has no defined target, and an intervention aimed at raising it is not obviously aimed at anything.

    [6] [13] [16]

  • Competition status

    Not quantified · MOTS-c is named on the World Anti-Doping Agency prohibited list itself, as an example of an activator of AMP-activated protein kinase under section S4.4.1, and section S4 is prohibited at all times, in competition and out of it. The analytical literature had discussed mitochondrial-derived peptides as emerging sports-drug-testing targets well before that. Any athlete subject to testing should still confirm current status against the governing body's own list for the current year rather than against this page.

    [3]

  • Unverified identity and purity of unapproved material

    Not quantified · With no approved manufacturer, nothing about the sequence fidelity, concentration, or contaminant profile of material labeled MOTS-c is regulated or independently guaranteed. This is a category-level risk that sits on top of whatever the molecule itself does.

    [14]

Published lists are never exhaustive, so report anything unexpected to a licensed provider.

Storage, handling & reconstitution

Lyophilized storage
Lyophilized MOTS-c is conventionally kept refrigerated at 2–8 °C and protected from light, with freezing used for long-term holding. The published MOTS-c literature is concerned with the peptide's biology rather than with vial shelf life. No stability study for this peptide exists, so the handling conventions here come from general lyophilized-peptide practice.
Reconstituted storage
Once in solution, peptides are conventionally refrigerated at 2–8 °C, protected from light, and treated as short-dated rather than indefinitely stable. No published study establishes a solution shelf life for MOTS-c.
Reconstitution diluent
Bacteriostatic water is the conventional diluent for lyophilized research peptides, including MOTS-c; it is sterile water preserved with 0.9% benzyl alcohol. Sterile water without a preservative is used where a preservative is contraindicated and is treated as single-use.
Reconstitution & handling
Conventional handling: sanitize the stopper before piercing it, add the diluent slowly down the inside wall of the vial rather than directly onto the powder, and let it dissolve on its own. Swirl gently if needed; never shake. A properly reconstituted solution is clear; anything cloudy, discolored, or carrying visible particulate is discarded. PHL does not publish volume or unit calculations, because those are dosing decisions and dosing decisions belong with a licensed clinician.
Handling notes
MOTS-c has no FDA-approved manufacturer, so there is no label, no assigned beyond-use date, and no lot-level stability testing behind any storage claim. Everything above is convention, not specification.

The how-to guides cover the conventions behind these fields, and what the published stability data does and does not establish: Storage, Reconstitution, Handling.

Goal pages that include MOTS-c

Each one starts from the goal rather than the molecule, and grades what the evidence supports for that goal specifically.

  • Anti-Aging

    A research reference for the compounds mapped to longevity and healthy aging. It sets out what the randomized human trials of oral NAD+ precursors and DHEA actually measured, why the injected forms have no outcomes evidence at all, and where the rest is mice and cell culture.

  • Endurance

    A research reference for the compounds mapped to aerobic capacity and stamina. Every one of them is prohibited in tested sport at all times, and only one has a randomized human trial using an endurance endpoint.

Questions for your provider

Bring this page to a licensed provider. A provider can order labs, review your medications and history, and tell you whether anything here is relevant to your situation. This page can't. Peptide Health Lab does not prescribe and does not sell peptides.

Want a structured starting point for that conversation? The Stack Builder turns your goals into a research-cited outline you can review together.

Citations

16 sources · every identifier checked against PubMed

Before you act on any of this

This page is educational only and is not medical advice. It does not diagnose, treat, or prescribe. Review it with a licensed provider before making any health decision. Peptide Health Lab does not sell peptides.

How we grade and verify evidence · Terms of Use · Privacy Policy

Open the Stack Builder